Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

The number of critical patients having to travel interstate to receive CAR T-cell therapy will be reduced from mid-next year, ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...

An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...

Looking to build a new laboratory or expand your existing facility. Talk to your Formaspace Design Consultant about our custom lab furniture solutions, built in the USA, at our Austin, Texas, factory ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

"ALA-CART improves the ability of CAR-T cells to detect and attack resistant cancer cells more effectively. This could lead to longer lasting results, even when other treatments have failed," said M.